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Summary Growth of cells in vitro in the presence of fatty acids can alter the membrane composition and
hence fluidity and permeability. Exposure of both doxorubicin (2780AD) and cisplatin (2780CP) resistant
human ovarian cell lines to non-toxic concentrations of polyunsaturated fatty acids (y-linolenic acid and
eicosapentaenoic acid) either before or during exposure to the cytotoxic drug did not modulate drug
sensitivity. However, the fatty acids were toxic in their own right. Whilst the ovarian cell lines 2780AD and
2780CP showed a small degree of cross resistance to both fatty acids the doxorubicin resistant breast cell line
MCF7/Adr was slightly more sensitive than MCF7. When the interactions between the polyunsaturated fatty
acids and cytotoxic drugs were analysed by the isobologram method the toxicities were shown to be additive.
The combination of polyunsaturated fatty acids and cytotoxic drugs may have clinical potential provided that
the normal tissue toxicities of the two treatments are not additive.
Several studies have suggested that changes in the plasma
membrane structure and lipid composition are associated
with the development of drug resistance in cell lines in vitro
(Peterson et al., 1983; Rintoul & Center, 1984; Wheeler et al.,
1982). The degree of structural order of plasma membrane
lipids was found to be higher in doxorubicin resistant P388
murine leukaemia cells than in drug sensitive parental cells
(Ramu et al., 1983) and a correlation between membrane
fluidity and resistance to doxorubicin was observed in a series
of Sarcoma 180 sublines (Siegfried et al., 1983). Furthermore,
differences were noted in the lipid composition of the cell
membrane between a human ovarian cancer cell line and a
cisplatin resistant variant and this was suggested to account,
in part, for decreased cellular drug accumulation (Mann et
al., 1988).
Membrane fluidity is determined by the degree of unsatur-
ation of the fatty acid residues in the component phospho-
lipids and by the cholesterol content. Cholesterol decreases
membrane fluidity by interfering with the orderly packing of
the lipids' fatty acid side chains. Over one half of the fatty
acid residues of animal lipids are unsaturated, i.e. contain
double bonds, and are often polyunsaturated, i.e. contain
two or more double bonds. Saturated fatty acids are highly
flexible molecules because there is relatively free rotation
about each of their carbon-carbon bonds. Fatty acid double
bonds almost always have the cis configuration and this puts
a rigid 300 bend in the hydrocarbon chain that interferes with
their efficient packing. The melting point of fatty acids
decreases with the degree of unsaturation. Similarly, lipid
fluidity increases with the degree of unsaturation of the com-
ponent fatty acids. Obviously the fluidity of biological memb-
ranes is one of their important physiological properties since
it determines the ability of the associated proteins, such as
receptors, ATPases and ion channels, to move and interact
(Spector & Burns, 1987). There have been a number of
reports suggesting that alteration of protein kinase C activity
can alter cellular sensitivity to both cisplatin and doxorubicin
(Basu et al., 1991; Fine et al., 1988; Hofmann et al., 1988;
Isonishi et al., 1990). Protein kinase C migrates to the cell
membrane when activated. Alterations of the membrane
composition could therefore alter protein kinase C activity
and hence cisplatin sensitivity. Fluidity will also influence
membrane permeability and this is particularly relevant to
many cytotoxic drugs such as doxorubicin and cisplatin,
which are thought to enter the cell by passive diffusion
(Siegfried et al., 1985; Andrews & Howell, 1990).
The lipid composition of cultured cells can be altered by
addition of fatty acids to the growth medium. It has already
been shown that incorporation of docosahexaenoic acid into
the membrane lipids of both doxorubicin and cisplatin resis-
tant human small cell lung cancer cell lines sensitises the cell
to the respective cytotoxic drug (Timmer-Bosscha et al.,
1989; Zijlstra et al., 1987). We have, therefore, determined
the effects on the sensitivity to both cisplatin and doxorubicin
of exposure of drug resistant cell lines to two polyun-
saturated fatty acids. The two polyunsaturated fatty acids
y-linolenic acid and eicosapentaenoic acid, were chosen since
they have been shown to be selectively toxic to tumour cells
in their own right (Begin et al., 1986a & b). y-Linolenic acid
is a major component of evening primrose oil (Wright &
Burton, 1982) and eicosapentaenoic acid is a major compo-
nent of fish oils (Murro, 1983).
Materials and methods
Materials
Cis-diamminedichloroplatinum(II) (cisplatin) and 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
were purchased from Sigma Chemical Co. (Poole, Dorset,
UK). Doxorubicin was obtained from Farmitalia (St Albans,
Herts, UK).
Polyunsaturatedfatty acids
Two polyunsaturated fatty acids, y-linolenic acid and
eicosapentaenoic acid were a gift from Scotia Pharmaceu-
ticals Ltd. (Surrey, UK). Both were supplied as oils and the
purity was 99% for y-linolenic acid and 90% for eicosapen-
taenoic acid. They were solubilised in ethanol and sterilised
by filtration (Millex-GV, Millipore Ltd., Watford, Herts,
UK) at a stock concentration of 80 mg ml1'. Aliquots were
stored in the dark at - 70°C in sealed vials purged with
nitrogen.
Cell lines
The human ovarian cell line A2780 and two drug resistant
sublines, 2780AD and 2780CP, were obtained from Dr R.F.
Ozols (Fox Chase Cancer Centre, Philadelphia, USA). They
were maintained in Roswell Park Memorial Institute 1640
(RPMI1640) medium containing glutamine (2 mM), foetal
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calf serum (10%) and insulin (0.25 unitsml'). The doxo-
rubicin resistant cell line, 2780AD, was grown routinely in
the presence of doxorubicin (2 JiM) but drug was removed for
5 days before use in experiments. Cell line 2780CP shows
stable resistance to cisplatin for up to 6 months in culture.
The human breast cancer cell line MCF7 and a doxoru-
bicin resistant subline MCF7/Adr were obtained from Dr K.
Cowan (National Cancer Institute, Bethesda, USA). They
were grown in RPM11640 medium containing glutamine
(2 mM) and foetal calf serum (10%). Cell line MCF7/Adr
was exposed to doxorubicin (1O LM) for 24 h every 6 weeks.
Cytotoxicity assay
Drug sensitivity was determined by a tetrazolium dye based
microtitration assay as described previously (Plumb et al.,
1989). Briefly cells were plated out at a density of 2 x 103
(2780AD and MCF7/Adr) or 5 x 102 (A2780, 2780CP and
MCF7) cells per well in 96 well flat bottomed plates (Linbro
from ICN Biomedicals Ltd., High Wycombe, Bucks, UK)
and allowed to attach and grow for 2 days. They were
exposed for various times to the cytotoxic drugs and polyun-
saturated fatty acids either alone or in combination as speci-
fied and then fed with fresh medium daily for 3 days. On the
4th day, cells were fed with medium containing Hepes buffer
(10 mM) and MTT (50 1tl, 5 mg ml-') was added to each well.
Plates were incubated in the dark at 37TC for 4 h, medium
and MTT removed and MTT-formazan crystals dissolved in
dimethyl sulphoxide (200Ill/well). Glycine buffer (25itl/well,
0.1 M, pH 10.5) was added and the absorbance measured at
570 nm in a multi-well plate reader (Model 3550 EIA reader,
Bio-Rad, Hemel Hempstead, Herts., UK).
A typical dose response curve consisted of eight drug
concentrations and four wells were used per drug concentra-
tion. Within an experiment triplicate determinations were
made for each treatment and the three dose response curves
were obtained from separate plates. Results are expressed in
terms of the drug concentration required to kill 50% of the
cells (ID50) estimated as the absorbance value equal to 50%
of that of the cells in the control untreated wells. All experi-
ments reported are representative of at least two repeats.
Isobologram analysis
The interaction between the polyunsaturated fatty acids and
cytotoxic drugs was interpreted by isobologram analysis
according to the method described by Steel and Peckham
(1979). For construction of the isobolograms a relative drug
concentration of 1 was defined as the ID50 concentration of
the cytotoxic drug or polyunsaturated fatty acid alone. Since
the survival curves for both doxorubicin and cisplatin were
almost linear after log transformation they were used as the
first drug for estimation of the envelope of additivity (Steel,
1979).
Statistics
Statistically significant differences were determined by Stu-
dent's t-test.
Results
Cytotoxicity ofpolyunsaturatedfatty acids
The sensitivity of the three ovarian cell lines to the two
polyunsaturated fatty acids is shown in Table I. Also shown
is the toxicity of doxorubicin and cisplatin for comparison.
The doxorubicin resistant cell line 2780AD is approx-
imately 800 fold resistant to doxorubicin and shows cross
resistance (11 fold) to cisplatin whereas 2780CP is 19 fold
resistant to cisplatin but is not cross resistant to doxorubicin.
Both 2780AD and 2780CP were cross resistant to Ty-linolenic
acid and eicosapentaenoic acid but the resistance factors were
only 2.5 and 4.5 fold. For each cell line the two polyun-
saturated fatty acids were equally toxic (Table I, Figure 1).
In contrast, the breast cell line MCF7/Adr was about 560
fold resistant to doxorubicin, but was more sensitive
(P<0.05) to both polyunsaturated fatty acids than the
parental cell line MCF7 (Table I).
Sensitivity of the ovarian cell lines to cisplatin and doxorubicin
when exposed in the presence ofpolyunsaturatedfatty acids
The concentrations of the polyunsaturated fatty acids used
were chosen such that the fatty acid alone produced a cell
kill of less than 10%. Since A2780 was more sensitive to the
polyunsaturated fatty acids lower concentrations were used
for this cell line.
Eicosapentaenoic acid had no effect on the cisplatin sensi-
tivity of A2780 and 2780AD but increasect slightly the sen-
sitivity of 2780CP at all concentrations used (Table II) and
this increase was just significant (P<0.05). The lowest con-
centration of y-linolenic acid used (A2780, 2.5 lg ml-';
2780AD and 2780CP, 10 lOgml-') had no effect on platinum
sensitivity. However, higher concentrations produced a signi-
ficant decrease in the ID50 in A2780 (P<0.01) and 2780AD
(6 fold, P<0.001). For 2780CP the increase in sensitivity
was only just significant at the highest concentration used
(40 pg ml-', P<0.05). It should be noted that all ID50 con-
centrations are calculated using a control absorbance value
obtained from cells that were not exposed to either the
cytotoxic drug or to the fatty acids.
A 24 h co-exposure to polyunsaturated fatty acids and
doxorubicin had no effect on the sensitivity of any of the
three cell lines to doxorubicin.
Effect ofpre-exposure ofthe cell lines to polyunsaturatedfatty
acids on the cytotoxicity ofcisplatin and doxorubicin
The effects of a 48 h pre-exposure to polyunsaturated fatty
acids on the sensitivity of the three cell lines to doxorubicin
and cisplatin are shown in Table III. The most significant
effects were seen in cell line 2780CP. A 48 h pre-treatment
with y-linolenic acid (40 figml -, 143.7 rM) and eicosapen-
taenoic acid (40,gml -m1, 132.2pM) sensitised 2780CP to cis-
platin by 8 and 10 fold respectively (P<0.001). This effect
was also apparent, but less marked after pre-exposure for
24 h. A 48 h pre-treatment with y-linolenic acid and eicosa-
Table I Sensitivities ofthehuman ovariancell line A2780 and its doxorubicin (2780AD)
andcisplatin (2780CP) resistantvariants to y-linolenic acid (GLA), eicosapentaenoic acid
(EPA), doxorubicin (DOX) and cisplatin (CP)
ID50 ("M)
A2780 2780AD 2780CP MCF7 MCF7/Adr
GLA 73±4 268±3*** 327±3*** 266±31 156±6*
EPA 95±2 208 12** 326± 10** 275± 16 191 ± 5*
DOX 0.0030±0.0003 2.4±0.1*** 0.0030±0.0003 0.08±0.01 44.9± 1.1***
CP 0.27±0.02 3.1±0.2*** 5.1 ± 1.0*** ND ND
Also shown are the sensitivities ofthe human breast cell line MCF7 anditsdoxorubicin
resistant variant (MCF7/Adr) to polyunsaturated fatty acids and doxorubicin. Cellswere
exposed to the individual agent for 24 h and results are the mean± standard error of
triplicate determinations from one representative experiment. Statistically significant
differences from the sensitivity of the parental cell line (A2780 or MCF7) are shown by
asterisks (*P<0.05, **P<0.01, ***P<0.001). ND = not done.730 J.A. PLUMB et al.
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Figure 1 Sensitivity of the three ovarian cell lines to y-linolenic
acid a, and eicosapentaenoic acid b. Cells were exposed to the
fatty acids for 24 h and cell survival was determined 3 days later
by MTT dye reduction. Cell survival is expressed as a percentage
of the absorbance of the control untreated cells and points are
the mean±standard error of triplicate observations.
pentaenoic acid sensitised 2780CP to doxorubicin by 3.5 and
6 fold respectively (P<0.01, Table III).
Pre-exposure to the fatty acids for up to 48 h had little
effect on the sensitivities of A2780 and 2780AD to cisplatin
or on the sensitivity of A2780 to doxorubicin (Table III). The
sensitivity of 2780AD to doxorubicin was significantly in-
creased by pre-exposure to y-linolenic acid (2.5 fold,
P<0.01) and eicosapentaenoic acid (22 fold, P<0.001) for
48 h (Table III). This trend was also apparent after a 24 h
pre-exposure, but was only significant for eicosapentaenoic
acid (9 fold, P<0.01).
Studies of even more prolonged pre-treatment of the cells
with the fatty acids were confined to the most significant
interactions observed in the shorter pre-exposure periods.
Furthermore, the concentration of the fatty acids was reduc-
ed in an attempt to avoid excessive toxicity of the fatty acid
alone.
Pre-exposure to eicosapentaenoic acid for 72 h sensitised
2780AD to doxorubicin by 6.5 fold (10jgml-', 33 fM;
P<0.01) and 17 fold (20jgml-1, 66.1 isM; P<0.001). Pre-
exposure to y-linoenic acid for 72 h sensitised 2780CP to
cisplatin by 5.5 fold (10 igml-', 35.9 pM; P<0.01) and 315
fold (20 mgml-', 71.8 mM; P<0.001). However, it is clearly
apparent that sensitisation is due, at least in part to the
toxicity of the fatty acid itself (Figure 2).
Isobologram analysis
Since the concentrations of the fatty acids used were them-
selves toxic the interactions were re-analysed by the isobolo-
gram method. Figure 3a shows the concentrations of cisplatin
and y-linolenic acid which when combined for 24 h produce a
50% reduction in survival of cell line 2780CP. The dotted
line delineates the envelope of additivity. It is clear that the
majority of points lie within the envelope indicative of an
additive interaction. Figure 3b shows the concentrations of
doxorubicin and eicosapentaenoic acid which when combined
for 24 h produce a 50% reduction in survival of cell line
2780AD. Again the interaction appears to be additive.
Similar isobolograms were obtained when cells were exposed
to the fatty acids before exposure to the cytotoxic drugs.
Discussion
These results show clearly that both y-linolenic acid and
eicosapentaenoic acid are toxic to tumour cells lines. The
polyunsaturated fatty acids were shown in some cases to
sensitise the cells to cytotoxic drugs. However, when the drug
interactions were analysed by the isobologram method the
interactions were clearly additive and not supra-additive.
Surprisingly, the doxorubicin and cisplatin resistant ovar-
ian cell lines were cross resistant to the fatty acids although
the resistance factors were much smaller than those for the
selecting agent. Cross resistance was not a general feature of
multidrug resistant cell lines since the doxorubicin resistant
breast cell line showed a tendency towards greater sensitivity
to the fatty acids than the parental cell line and this supports
previous observations (Sircar et al., 1990).
The results are consistent with previous studies which have
shown that polyunsaturated fatty acids have direct antineo-
plastic activities and that tumour cells differ in their sensi-
tivities to polyunsaturated fatty acids (Abou et al., 1988;
Karmali et al., 1985). The mechanisms by which polyunsatu-
rated fatty acids kill cells is unknown but there is evidence to
suggest that toxicity may be related to lipid peroxidation and
Table II Sensitivities of the ovarian cell lines to cisplatin when exposed for 24 h in the
presence or absence of polyunsaturated fatty acids
ID50(gUM)
A2780 2780AD 2780CP
Cisplatin 0.49±0.08 5.0±0.3*** 10.5± 0.6***
+y-linolenic acid (2.5) 0.36±0.05 (10) 4.7±0.3 12.2±0.8
(ggml-') (5) 0.13±0.04** (20) 3.0±0.3** 9.4±0.5
(10) 0.06±0.01** (40) 0.82±0.15*** 6.1 ±0.8*
+eicosapentaenoic (2.5) 0.46±0.06 (10) 6.2±0.5 8.3± 0.5*
acid sgml-') (5) 0.60±0.05 (20) 3.9±0.7 8.0±0.3*
(10) 0.40±0.02 (40) ND 8.1 ± 1.0*
Valuesarethemean±standarderroroftriplicatedeterminations fromonerepresentative
experiment. Theconcentration(jugml-')ofthefattyacidusedwaslowerforA2780thanfor
the other two cell lines and is shown in parentheses. Statistically significant differences in
sensitivity when compared with exposure to cisplatin alone are shown by asterisks (*P<00.; **P<0.01; ***P<0.001). ND = not done.
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Table m Sensitivities of the ovarian cell lines to cisplatin and doxorubicin when exposed to
polyunsaturated fatty acids for 48 h before exposure to cisplatin or doxorubicin alone for 4 h
ID50 (AM)
A2780 2780AD 2780CP
Doxorubicin 0.022±0.001 8.9±0.5 0.080±0.006
+ y-linolenic acid (,ugml-') (2.5) 0.016±0.003 (40) 3.5±0.2** 0.023±0.004**
+eicosapentaenoic acid (ugml-') (2.5) 0.018±0.004 (40) 0.4±0.1*** 0.013±0.002**
Cisplatin 0.79±0.01 13.2±0.5 26.8±0.8
+ y-linolenic acid (gml-') (2.5) 0.50±0.06* (40) 19.0± 1.7 3.3± 1.1***
+ eicosapentaenoic acid (ILgml') (2.5) 0.65±0.14 (40) 8.7±1.7 2.7±0.6***
Values are the mean±standard error oftriplicate determinations from one representative experiment.
Theconcentration(#gml-')ofthefattyacidusedwaslowerforA2780thanfortheothertwocelllinesand
is shown inparentheses. Statistically significant differences in sensitivity whencomparedwithexposure to
cisplatin or doxorubicin alone are shown by asterisks (*P<0.05, **P<0.01, ***P<0.001).
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Figure 2 Dose response curves for cell line 2780CP exposed to
cisplatin for 4 h after pretreatment of the cells with a y-linolenic
acid for 72 h. Three concentrations of y-linolenic acid were used
(shown as tLg ml-') and cell survival is expressed as absorbance
per well. Results are the mean ± standard error of triplicate
plates.
production of superoxide radicals (Begin et al., 1988; Das et
al., 1987). This is supported by the observation that the
toxicity of T-linolenic acid in human neuroblastoma cells in
vitro is inhibited by antioxidants (Fujiwara et al., 1984). The
most cytotoxic polyunsaturated fatty acids appear to be
those with 3, 4 or 5 double bonds and these include eico-
sapentaenoic acid and y-linolenic acid. Docosahexaenoic acid
which has six double bonds is much less toxic to cells (Begin
et al., 1986a). Furthermore, eicosapentaenoic acid and y-
linolenic acid are more potent in terms of lipid peroxidation
and superoxide radical formation than docosahexaenoic acid.
Part of the selective toxicity of polyunsaturated fatty acids to
tumour cells might be explained by altered activities of
enzymes that metabolise these acids. Both delta 6- and 5-
fatty acyl-CoA desaturases have been shown to be impaired
or absent in some tumour cell lines (Howards & Howard,
1974; Maeda et al., 1978).
Initial studies of the interactions between polyunsaturated
fatty acids and the cytotoxic drugs were designed to deter-
mine whether there is an acute effect of the fatty acid on
cellular drug sensitivity. Co-incubation of cells with the poly-
unsaturated fatty acids had varying effects on cell survival
depending on the cell line and the fatty acid used. The most
significant interactions were observed between -y-linolenic acid
and cisplatin. y-Linolenic acid sensitised all three ovarian cell
lines to cisplatin and the effect was dose dependent (Table
II). This combination was, however, least effective in the
cisplatin resistant cell line 2780CP. In contrast, eicosapen-
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Figure 3 Isobolograms for the interaction between y-linolenic
acid and cisplatin in cell line 2780CP a, and eicosapentaenoic acid
and doxorubicin in cell ine 2780AD b. Cells were exposed to the
cytotoxic drug for 24 h in the presence of the fatty acid. The ID"
was used to define a relative drug concentration of 1 and the
dotted lines define the envelope of additivity. Points are the
concentrations (expressed relative to the ID50 concentration) of
the two agents which when combined kill 50% of the cells.
taenoic acid had no effect on the sensitivity of cell lines
A2780 and 2780AD to cisplatin but produced a slight in-
crease in sensitivity in cell line 2780CP (1.3 fold, P<0.05,
Table II). Neither of the polyunsaturated fatty acids had any
effect on doxorubicin sensitivity of the three cell lines.
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In an attempt to enhance the sensitising effects of the
polyunsaturated fatty acids cells were pre-incubated with the
polyunsaturated acids before exposure to the cytotoxic drugs.
The rational behind this approach was based on the assump-
tion that pretreatment with the fatty acids would have one of
two effects. Either they would make the cells more sensitive
to subsequent exposure to a second cytotoxic agent or pre-
exposure would allow the fatty acids to become incorporated
into the cellular lipids and thus alter membrane fluidity.
Exposure to the polyunsaturated fatty acids for 24 h before
exposure to cisplatin was less effective for 2780AD than
co-exposure. However, it should be noted that for these
experiments the exposure time to cisplatin and doxorubicin
was reduced to 4 h and this may well explain this difference.
A 48 h pre-treatment period had marked effects on the
sensitivity of 2780CP to cisplatin (Table III). Both eicosapen-
taenoic acid and y-linolenic acid were equally effective (10
and 8 fold sensitisation respectively P<0.001). This was
surprising since T-linolenic acid was more effective than
eicosapentaenoic acid when a 24 h pretreatment period was
used (5.6 fold c.f. 1.4 fold). Both polyunsaturated fatty acids
sensitised 2780AD and 2780CP to doxorubicin when cells
were pre-treated for 48 h (P<0.01, Table III).
In order to ensure that the polyunsaturated fatty acids
would be incorporated into cellular phospholiopds at 72 h
pre-treatment protocol used by Zijlstra et al. (1987) and
Timmer-Bosscha et al. (1989) was followed. For these experi-
ments the concentration of the fatty acids was reduced and
the fatty acid was replaced after 48 h. The stability of eico-
sapentaenoic acid and y-linolenic acid in culture meidum is
not known so the exact exposure time may be less than 72 h.
Only the interactions between eicosapentaenoic acid and
doxorubicin in 2780AD and between y-linolenic acid and
cisplatin in 2780CP were examined and the results were
consistent with the trends already observed for the shorter
pre-exposure periods. However, these experiments also show
clearly that part, if not all, of the apparent sensitisation is
due to the toxicity of the fatty acid alone (Figure 2). Thus at
the highest concentration of y-linolenic acid used for pre-
treatment of 2780CP the fatty acid alone killed more than
50% of the cells and it was not possible to determine an IDm
concentration for cisplatin. If cell survival is expressed as a
percentage of the control where the control for 'y-linolenic
acid exposure is cells exposed to y-linolenic acid alone for
72, it is possible to compare treatments. However, the para-
meter derived from this approach is not an ID50. It is
assumed that the effect of y-linolenic acid alone on cell
survival is constant regardless of the concentration of cis-
platin used. Clearly when studying the interaction of two
drugs it would be wrong to assume that y-linolenic acid
increases cisplatin toxicity but not vice versa.
Since the toxicity of the fatty acid alone was apparent in
all pretreatment experiments drug interactions were subject
to a more critical analysis. The isobologram method describ-
ed by Steel and Peckham (1979) was originally designed for
studies of the interactions between radiation and cytotoxic
drugs (Steel, 1979) and it has been used successfully to study
interactions between a variety of agents (Carter & Wampler,
1986; Church et al., 1988; Gessner, 1988). Application of this
method of analysis to the interaction between y-linolenic acid
and cisplatin showed clearly that the two agents demonstrate
additive toxicities (Figure 3a) since the majority of the points
lie within the envelope of additivity. Additive toxicities were
also demonstrated for eicosapentaenoic acid and doxorubicin
(Figure 3b). These observations are entirely consistent with
previous reports that polyunsaturated fatty acids can sensitise
drug resistant cell lines to cytotoxic drugs (Timmer-Bosscha
et al., 1989; Zijlstra et al., 1987). Zijlstra et al. (1987) showed
that the doxorubicin resistant cell ine GLC4/ADR was more
sensitive to docosahexaenoic acid than the parental cell line
GLC4 and was sensitised to doxorubicin by 72 h pretreat-
ment with the fatty acid whereas GLC4 was not sensitised.
Similarly, docosahexaenoic acid sensitised the cisplatin resis-
tant subline GLC4 CP to cisplatin, but did not sensitise GLC4
(Timmer-Bosscha et al., 1989). The authors were unable to
explain this sensitisation since cellular platinum concentra-
tions, total DNA bound platinum and the amount of the
major DNA-platinum adducts increased in both cell lines.
The sensitisation could well be explained if GLC4CP, like
GLC4/ADR, is more sensitive to docosahexaenoic acid than
GLC4.
These results suggest that eicosapentaenoic acid and y-
linolenic acid do not have a role as resistance modulators in
drug resistant cell lines. However, additive toxicity can be of
great value in the clinic provided that the toxicities of the
two drugs in normal tissues are non-additive. High concen-
trations of polyunsaturated fatty acids have been given to
both animals and man without apparent toxicity (Dodge,
1990; Van der Merwe et al., 1987; Zhu et al., 1989). Since it
is known that tumour cells derive most of their fatty acids
from the host circulation it should be possible to deliver
polyunsaturated fatty acids to tumour cells, perhaps preferen-
tially. This aspect has already been exploited using eicosapen-
taenoic acid in an attempt to reduce the cachexia associated
with growth of some tumours and, indeed, inhibition of
tumour growth has been observed (Beck et al., 1991; Tisdale
& Beck, 1991).
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